• Publications
  • Influence
Apixaban versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Expand
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE
TLDR
In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events. Expand
Apixaban in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage. Expand
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.
TLDR
Overall, dual-chamber pacing offers significant improvement as compared with ventricular pacing, and reduces the risk of atrial fibrillation, reduces signs and symptoms of heart failure, and slightly improves the quality of life. Expand
Ventricular dysfunction and the risk of stroke after myocardial infarction.
TLDR
During the five years after myocardial infarction, patients have a substantial risk of stroke and a decreased ejection fraction and older age are both independent predictors of an increased risk of Stroke. Expand
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time
TLDR
For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy, and a wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries. Expand
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
TLDR
Evidence of inflammation after MI is associated with increased risk of recurrent coronary events, and therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent. Expand
Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study.
TLDR
Age and left ventricular ejection fraction were the most important predictors of HF, and diabetes, history of hypertension, previous MI, and baseline heart rate were independently associated with a 30% lower risk of HF. Expand
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
TLDR
The data suggest that in patients with atrial fibrillation and a history of congestive heart failure, the risk of antiarrhythmic drug therapy may outweigh the potential benefit of maintaining sinus rhythm. Expand
Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
TLDR
Patients with asymptomatic AF have less serious heart disease but more cerebrovascular disease; however, the absence of symptoms and the differences in treatment does not confer a more favorable prognosis when differences in baseline clinical parameters are considered. Expand
...
1
2
3
4
5
...